Investor Presentaiton

Performance: continuing operations basis for guidance Historical financials, adjusted results 2021 2022 Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Including COVID-19 solutions Sales (£m) 5,155 5,838 6,627 7,076 24,696 7,190 6,929 7,829 7,376 29,324 Operating profit (£m) 1,325 1,641 2,209 1,318 6,493 1,943 2,008 2,605 1,595 8,151 Earnings per share (pence) post- 21.1 28.2 37.4 23.6 110.3 32.3 34.7 46.9 25.8 139.7 share consolidation COVID-19 solutions impact Sales 276 209 920 1,405 1,307 466 417 183 2,373 Operating profit (12) 233 97 214 532 194 58 141 69 462 Earnings per share (pence) post- share consolidation (0.2) 4.8 1.9 4.7 11.2 4.1 1.2 2.9 1.5 9.7 GSK 35

View entire presentation